
Opinion|Videos|February 26, 2024
LIGHTHOUSE Trial and The Role of 18F-rhPSMA-7.3 for Staging of Prostate Cancer
Dr. Chapin and fellow expert oncologists discuss the latest data from the LIGHTHOUSE trial, evaluating 18F-rhPSMA-7.3 for staging patients with prostate cancer.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Experts discuss the challenge of detecting CIS in bladder cancer
2
Study shows durable 3-year outcomes with first-line gemcitabine/docetaxel in NMIBC
3
Phase 3 trial launches of CAIX-targeted radiopharmaceutical for ccRCC
4
Kathryn Gessner, MD, PhD, on the challenges of selecting patients for bladder preservation
5













